Popular wellness trend is supposed to help with weight loss — but it may make you eat more
While the ostensible point of most wellness trends is to promote good physical and mental health — as opposed to purely shedding pounds — weight management is often an added perk.
But a fascinating new study published in the journal Physiology & Behavior warns that the caloric dump of one popular practice might be mostly in your head.
Cold plunges and ice baths have made quite the splash in recent years, thanks to their purported boost in mental clarity, blood circulation and metabolism and their reduction in muscle soreness and stress.
And if you've ever spent time in freezing water, you've probably noticed a significant uptick in your appetite — leading you to naturally believe you've really earned that burger.
Sadly, it seems that might not be the case.
Researchers suspect that the 'after-drop' effect — where core body temperature keeps falling after cold exposure, even when you're out of the water — triggers brain regions linked to temperature and energy, boosting appetite.
'Ice baths and cold dips have become really popular, with many people hoping they'll help with weight loss,' David Broom, a professor at UK's Coventry University Research Center for Physical Activity, Sport and Exercise Sciences, said in a statement.
'But our findings show that while cold water does make your body work harder and burn more energy, it also leads to eating more afterward — possibly undoing the potential weight-loss benefits,' he continued.
'Interestingly, people didn't say they felt hungrier during or after the cold water — they just ate more.'
Researchers asked 10 men and five women who were active and healthy to spend 30 minutes in cold water (60 degrees Fahrenheit), hot water (95 degrees) or room temperature water (78 degrees).
Afterwards — in what sounds like the best controlled trial ever — they were asked to eat a plate of pasta until 'comfortably full.'
Of the three groups, the cold water cohort ate a whopping 240 extra calories.
Depending on various factors, spending 30 minutes in a cold plunge — which is, by the way, not really recommended by experts, who advise shooting for no more than 10 minutes due to risk of hypothermia — only burns an estimated 250 to 500 calories, which is why probably why researchers say the overeating might negate the burn.
For what it's worth, these findings align with what experts say about contrast therapy — the art of repeatedly alternating between hot and cold, like shvitzing in a sauna and then jumping into a cold plunge, as one does in modern bathhouses and traditional Finnish culture.
Dr. Hany Demian, CEO of BioSpine and co-founder of Pain Care Clinics, previously told The Post that contrast therapy burns 'a very small amount of calories, but nothing significant.'
He added that the surge in hunger has more to do with 'stomach contraction and relaxation, which stimulates the appetite.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a minute ago
- Medscape
UK Clinicians Want Clearer AI Guidance and Oversight
Artificial intelligence (AI) is playing a growing role in healthcare worldwide, but UK clinicians remain cautious, citing practical and ethical concerns, research has revealed. Alongside rising global adoption, regulators are moving to address safety and trust. The Medicines and Healthcare products Regulatory Agency (MHRA) has joined as a founding member of the new Health AI Global Regulatory Network, positioning the UK at the forefront of international oversight. Global Uptake Rising, UK Lags Behind Elsevier's Clinician of the Future 2025 report, published last month, surveyed 2206 clinicians (1781 doctors and 425 nurses) in 109 countries. The responses included answers from 78 UK doctors or physician associates and 31 nurses. Nearly half of respondents globally (48%) reported using AI at work, almost double the 2024 figure of 26%. In the UK, uptake was lower. Only 34% of UK clinicians reported using AI at work, with just 21% of doctors doing so. Common uses included identifying drug interactions (20%), writing clinical notes (18%), second opinions (18%), patient letters (16%), analysing medical images (15%), medication summaries (12%), and multidisciplinary reviews of complex cases (8%). Despite high patient volumes — 60% of UK clinicians said they lacked time to deliver good care, compared with 74% globally — many felt digital diagnostic tools remained inadequate. Scepticism and Distrust UK clinicians were more sceptical than average about AI's potential benefits and were less likely to use it for clinical decision-making, with 53% indicating they would not, and 45% saying they would not rely on AI tools for second opinions. Thirty-three percent described AI as unreliable, compared with 23% who considered it trustworthy. Dr Rahul Goyal, clinical executive at Elsevier and a practising GP, told Medscape News UK that caution reflects the NHS's structure. He cited strict regulatory oversight, national guidelines, evidence-based practice, and accountability as factors. 'While these priorities help safeguard patient care, they can also make clinicians more cautious about adopting new technologies like AI,' he said. He also pointed to 'tech debt' within NHS systems, with many still paper-based and lacking routine clinical decision support. 'As a result, clinicians are understandably more sceptical about using new technologies,' Goyal said. Confidentiality and Trust Most Key When asked what would increase their confidence in AI, 81% of UK clinicians highlighted data confidentiality. The same proportion wanted AI tools trained for factual accuracy, morality, and safety — well above the 63% global average. Trust in international governance was low. Just 27% of UK respondents said they trusted their organisation's AI oversight. Globally, 74% said clearer guidance on AI use would boost trust. The findings align with concerns expressed in Medscape's September 2024 UK Doctors and AI Report. It found that while more than half of clinicians were enthusiastic about the future of AI in healthcare, 1 in 3 of the 745 respondents lacked confidence that it could ensure confidentiality. The vast majority (83%) agreed there was a need for oversight of AI in healthcare settings. Push for Regulation A General Medical Council report earlier this year echoed these concerns, with doctors warning that NHS IT systems must improve before wider adoption. Respondents highlighted concerns about confidentiality risks, over-reliance, de-skilling, errors, and lack of independent evaluation. Many called for regulators to provide more guidance. The lower adoption rate of AI in the UK 'underscores the prevailing caution, and reinforces the need for greater integration, clear guidance, and reassurance as AI becomes more prominent in UK healthcare,' Goyal said. He expressed support for the MHRA's leading role in the new Health AI Global Regulatory Network, describing it as 'a proactive step toward addressing clinicians' concerns.' AI and digital tools are reshaping healthcare, he said, but 'their success depends on building systems that empower clinicians to use them confidently and responsibly.' Looking Ahead While concerns persist, many clinicians see potential benefits. Nearly half (46%) of UK respondents said AI could improve consultation quality, and 62% expected it to improve patient outcomes within 3 years. Goyal said that success depends on integration into NHS systems, clinician training, and patient acceptance. 'If AI is used as a tool to improve access, enhance communication, and empower patients with information, then it is a win,' he said. 'However, if it is poorly implemented or perceived as impersonal, it could widen the gap between GPs and patients.'
CNN
2 minutes ago
- CNN
UK regulator bans shower gel ad for perpetuating racial stereotypes
UK Fashion and beauty Race & ethnicityFacebookTweetLink Follow UK regulators have banned a TV commercial for Sanex shower gel after ruling that it 'could be interpreted as suggesting that white skin was superior to black skin.' The Advertising Standards Authority (ASA) acted after receiving complaints about the ad from two people 'who believed the ad perpetuated negative stereotypes about people with darker skin tones,' it said in a statement Wednesday. The spot, which aired in June, featured a Black model whose skin is covered with red scratch marks and another covered with a cracked material that looks like clay. 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24-hour hydration feel,' a voice-over said, accompanying video of a White woman showering. 'Relief could be as simple as a shower,' it added. US consumer products company Colgate-Palmolive, which owns the Sanex brand, said the fact that the ad featured models with different skin tones demonstrated its commitment to diversity, according to the ASA's statement. The regulator said Colgate-Palmolive believed 'the depiction of diverse models in the ad, either experiencing skin discomfort or post-product relief, was utilised in a 'before and after' scenario to show their product was suitable and effective for all, rather than as a comparison based on race or ethnicity.' Clearcast, a company that checks whether TV commercials follow the UK Code of Broadcast Advertising before they can be aired, also said the ad demonstrated the inclusivity of Sanex. While the ASA accepted the argument that the ad showed 'before and after' scenarios to demonstrate the effectiveness of the product, it ruled that its structure was problematic. 'It was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved,' the statement said. 'That could be interpreted as suggesting that white skin was superior to black skin,' it added, while acknowledging that 'we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers.' The ASA added that it had concluded the ad had breached the broadcast advertising code and was likely to cause serious offense. CNN has contacted Colgate-Palmolive for comment.
Yahoo
29 minutes ago
- Yahoo
Alligator Bioscience Provides Highlights from R&D Event 2025
LUND, SE / / August 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, provides key highlights from its R&D event held on 19 August 2025. The event featured presentations from Alligator's management and scientific leadership, outlining Alligator's clinical progress, upcoming milestones, and strategic outlook. Key takeaways from the event include: Mitazalimab - Phase 3 readiness : Long-term follow-up data continue to demonstrate encouraging overall survival in metastatic pancreatic cancer, supporting the confirmed regulatory path and planned initiation of a Phase 3 trial. Scientific insights : New translational biomarker data further expand and strengthen the rationale for mitazalimab in pancreatic cancer and other solid tumors, underscored by myeloid and T-cell activation and their correlation with improved clinical outcomes. Trial completion and CMC status: The final, 30-month, data read-out from OPTIMIZE-1 is expected during Q3 2025. The trial will thereafter be finalized, with mitazalimab being provided to patients still on treatment, and sites with ongoing patients remain open under limited, risk-based monitoring; manufacturing of Phase 3 material has been successfully completed. Investigator-initiated trials (IITs) : Based on the significant investigator interest Alligator is engaged in a number of externally funded exploratory and Phase 2 clinical trials with mitazalimab across pancreatic, gastrointestinal and other solid tumors to expand mitazalimab's future clinical use. Individual trials are expected to start during H2 2025 and the first half of 2026. Pipeline updates : The HER2 antibody HLX22 (developed by Chinese Henlius) has entered a global Phase 3 trial in gastric cancers. Alligator expects to receive the next development milestone within 6-12 months, and estimates that its share of the future royalties will amount to SEK 150-400 million annually. Strategic outlook : With a reduced burn-rate, Alligator is well positioned to advance mitazalimab into registrational trials together with a partner, and in parallel explore additional development options for the asset. Together mitazalimab and HLX22 represent a significant financial upside for Alligator. Other pipeline assets and technologies represent additional future development and income opportunities. A replay of the event is available through >>this link<< . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 12:15 p.m. CEST on 20 August 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience provides highlights from R&D event 2025 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire
